The global BRAF kinase inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). BRAF is a kinase enzyme that helps control cell growth and signalling. This enzyme can be found in a mutated form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. The major factor that is expected to drive the global BRAF kinase inhibitors market during the forecast period includes product approvals by regulatory bodies in various regions across the globe.
Moreover, the robust pipeline of BRAF kinase inhibitor drugs is expected to significantly drive the growth of the global BRAF kinase inhibitors market during the forecast period. Furthermore, the global BRAF kinase inhibitors market is anticipated to witness high growth during the forecast period, owing to the increasing incidence and prevalence of metastatic cancer.
To Request a Sample of our Report on Global BRAF Kinase Inhibitors Market: https://www.omrglobal.com/request-sample/braf-kinase-inhibitors-market
The global BRAF kinase inhibitors market analysis includes some of the key market players such as F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc., among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions.
Recent Development
For instance, in June 2020, BeiGene, Ltd., a commercial-stage biotechnology company and SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the presentation of preclinical data and provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene’s investigational RAF dimer inhibitor, lifirafenib, with SpringWorks’ investigational MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors harbouring mutations in the MAPK pathway, including those with RAS mutations.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
· Segment Covered
· Regions Covered- Globally
· Competitive Landscape: F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc., among others.
(Get 15% Discount on Buying this Report)
A full Report of Global BRAF Kinase Inhibitors Market is Available at: https://www.omrglobal.com/industry-reports/braf-kinase-inhibitors-market
Global BRAF Kinase Inhibitors Market by Segment
By Drug
• Vemurafenib
• Dabrafenib
• Lifirafenib
• Encorafenib
By Indication
• Metastatic Melanoma
• Metastatic Lung Cancer
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global BRAF Kinase Inhibitors Market by Regional Analysis
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
